We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...